Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Stintzing

Showing results (11-20 of 228) with videos related to

Pageof 23
Sort By:
Lancet (London, England)|September 21, 2024
Liver transplantation in metastatic colorectal cancer: a new standard of care?Volker Heinemann, Sebastian Stintzing
International Journal of Cancer|August 30, 2012
Author's reply to: "Prognostic value of cetuximab related skintoxicity in metastatic colorectal cancer patients and its correlation with parameters of the EGFR signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group"Sebastian Stintzing, Volker Heinemann
Journal of the National Cancer Institute|May 25, 2013
MicroRNA-21 in colorectal cancer: "Just another brick in the wall"?Sebastian Stintzing, Heinz-Josef Lenz
Journal of the National Cancer Institute|November 16, 2013
A small cog in a big wheel: PIK3CA mutations in colorectal cancerSebastian Stintzing, Heinz-Josef Lenz
Expert Opinion on Pharmacotherapy|August 15, 2013
Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!Sebastian Stintzing, Heinz-Josef Lenz
Nature Reviews. Clinical Oncology|August 15, 2012
Targeted therapies: Cetuximab dosing by rash--is the scaling of EVEREST meaningful?Sebastian Stintzing, Heinz-Josef Lenz
Journal of the National Cancer Institute|September 24, 2014
So much effort, so little progress?Heinz-Josef Lenz, Sebastian Stintzing
The Lancet. Oncology|July 3, 2019
Study evidence confirms current clinical practice in refractory metastatic colorectal cancer: the ReDOS trialRalf-Dieter Hofheinz, Sebastian Stintzing
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2014
Molecular pathways: turning proteasomal protein degradation into a unique treatment approachSebastian Stintzing, Heinz-Josef Lenz
Visceral Medicine|August 6, 2016
Treatment of Metastatic Colorectal Cancer: Standard of Care and Future PerspectivesJulian Holch, Sebastian Stintzing, Volker Heinemann
Pageof 23

Showing results (11-20 of 228) with videos related to

Sort By:
Pageof 23
Lancet (London, England)|September 21, 2024
Liver transplantation in metastatic colorectal cancer: a new standard of care?Volker Heinemann, Sebastian Stintzing
International Journal of Cancer|August 30, 2012
Author's reply to: "Prognostic value of cetuximab related skintoxicity in metastatic colorectal cancer patients and its correlation with parameters of the EGFR signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group"Sebastian Stintzing, Volker Heinemann
Journal of the National Cancer Institute|May 25, 2013
MicroRNA-21 in colorectal cancer: "Just another brick in the wall"?Sebastian Stintzing, Heinz-Josef Lenz
Journal of the National Cancer Institute|November 16, 2013
A small cog in a big wheel: PIK3CA mutations in colorectal cancerSebastian Stintzing, Heinz-Josef Lenz
Expert Opinion on Pharmacotherapy|August 15, 2013
Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!Sebastian Stintzing, Heinz-Josef Lenz
Nature Reviews. Clinical Oncology|August 15, 2012
Targeted therapies: Cetuximab dosing by rash--is the scaling of EVEREST meaningful?Sebastian Stintzing, Heinz-Josef Lenz
Journal of the National Cancer Institute|September 24, 2014
So much effort, so little progress?Heinz-Josef Lenz, Sebastian Stintzing
The Lancet. Oncology|July 3, 2019
Study evidence confirms current clinical practice in refractory metastatic colorectal cancer: the ReDOS trialRalf-Dieter Hofheinz, Sebastian Stintzing
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2014
Molecular pathways: turning proteasomal protein degradation into a unique treatment approachSebastian Stintzing, Heinz-Josef Lenz
Visceral Medicine|August 6, 2016
Treatment of Metastatic Colorectal Cancer: Standard of Care and Future PerspectivesJulian Holch, Sebastian Stintzing, Volker Heinemann
Pageof 23